Biosimilar Name Debate Heats Up As USP Says Zarxio Doesn't Need Suffix
Executive Summary
Determination that Zarxio meets monograph standards indicates product should carry same nonproprietary name as Neupogen, USP argues; FDA says monograph doesn't apply.